NCT06065189View on ClinicalTrials.gov

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Beta-Thalassemia
Interventions
BIOLOGICAL

CS-101 injection

Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Trial Locations (1)

201102

Children's Hospital of Fudan University, Shanghai

Sponsors
All Listed Sponsors
collaborator

CorrectSequence Therapeutics Co., Ltd

INDUSTRY

lead

Children's Hospital of Fudan University

OTHER